NKTR: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Cash Flow Overview

No enough data to generate the overview

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Revenue	33,425	-
Rezpegaldesleukin	37,888	-
NKTRZero One Six Five	8,931	-
NKTRTwo Five Five	5,034	-
Discovery Research And Other Programs	1,018	-
Clinical development, contract manufacturing and other third party costs	52,871	-
Employee costs	33,782	-
Facilities costs	9,378	-
Other operating costs	37,881	-
Other segment expenses	11,950	-
Total operating costs and expenses	145,862	-
Loss from operations	-112,437	-
Non-cash interest expense on liabilities related to the sales of future royalties	16,415	-
Interest income	7,662	-
Other income (expense), net	405	-
Total non-operating income (expense), net	-8,348	-
Loss before provision (benefit) for income taxes and equity method investment	-120,785	-
Provision (benefit) for income taxes	-169	-
Loss before equity method investment	-120,616	-
Loss from equity method investment	-7,381	-
Net loss	-127,997	-92,475
Non-cash royalty revenue related to the sales of future royalties	33,125	21,635
Non-cash interest expense on liabilities related to the sales of future royalties	16,415	10,368
Loss from equity method investment	-7,381	-6,847
Stock-based compensation	10,456	7,384
Depreciation and amortization expense	836	640
Impairment of right-of-use assets and property and equipment	0	0
Provision for net realizable value of inventory	0	0
Amortization of premiums (discounts), net	-3,626	-2,193
Accounts receivable	0	0
Inventory	0	0
Operating leases, net	9,407	5,580
Other assets	5,591	4,973
Accounts payable	4,168	2,886
Accrued expenses	-3,062	3,940
Net cash used in operating activities	-143,552	-94,791
Purchases of investments	193,410	43,852
Maturities of investments	192,691	137,892
Purchases of property and equipment	153	39
Payment of transaction costs and working capital adjustment from the sale of the huntsville manufacturing facility	697	697
Net cash provided by (used in) investing activities	-1,569	93,304
Proceeds from shares issued under equity compensation plans and other	456	218
Proceeds from offering, net-Two Thousand Twenty Five Secondary Public Offering	108,100	-
Proceeds from offering, net-At The Market Offering	34,489	-
Payments of offering costs associated with issuance of common stock	1,150	-
Proceeds from issuance of pre-funded warrant	0	0
Proceeds from sale of future royalties	0	0
Repurchase of common stock from bristol-myers squibb	0	0
Net cash provided by financing activities	141,895	218
Effect of foreign exchange rates on cash and cash equivalents	6	5
Net decrease in cash and cash equivalents	-3,220	-1,264
Cash and cash equivalents at beginning of period	44,252	-
Cash and cash equivalents at end of period	41,032	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

NKTR: the cashflow